Should You Buy Ovid Therapeutics Inc (OVID) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
1.550
1 Day change
52 Week Range
2.010
Analysis Updated At
2026/01/26
Ovid Therapeutics Inc (OVID) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. The stock lacks significant positive momentum, has weak financial performance, and no strong trading signals or catalysts to suggest immediate upside potential. Holding off for better opportunities or further developments is recommended.
Technical Analysis
The technical indicators show a neutral to slightly bearish trend. The MACD is below 0 and negatively contracting, RSI is neutral at 55.379, and moving averages are converging. The stock is trading close to its pivot level of 1.628, with resistance at 1.739 and support at 1.517. The overall technical picture does not suggest a strong buy signal.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
5
Buy
6
Positive Catalysts
Analysts have initiated coverage with positive ratings and price targets ranging from $2 to $5, citing promising clinical data for OV329 and its potential in the epilepsy therapy market. The FDA's interest in approving new drugs in this space is also a favorable factor.
Neutral/Negative Catalysts
No recent news or congress trading data is available to provide additional support.
Financial Performance
In Q3 2025, revenue dropped by -23.70% YoY to $132,000, net income fell by -13.19% YoY to -$12,158,000, and EPS decreased by -15.00% YoY to -0.17. While gross margin remained at 100%, the overall financial performance is poor.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts have provided positive ratings, with LifeSci Capital, Roth Capital, H.C. Wainwright, and Leerink initiating coverage with Outperform or Buy ratings. Price targets range from $2 to $5, indicating potential upside. However, these are long-term projections and do not align with current weak performance and sentiment.
Wall Street analysts forecast OVID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OVID is 4.17 USD with a low forecast of 2 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast OVID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OVID is 4.17 USD with a low forecast of 2 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.550
Low
2
Averages
4.17
High
7
Current: 1.550
Low
2
Averages
4.17
High
7
LifeSci Capital
Outperform
initiated
$4
AI Analysis
2025-12-22
Reason
LifeSci Capital
Price Target
$4
AI Analysis
2025-12-22
initiated
Outperform
Reason
LifeSci Capital initiated coverage of Ovid Therapeutics with an Outperform rating and $4 price target.
Roth Capital
Boobalan Pachaiyappan
Buy
initiated
$3
2025-12-11
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$3
2025-12-11
initiated
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Ovid Therapeutics with a Buy rating and $3 price target. The firm views Ovid's OV329 as a "differentiated" oral agent targeting a sub-population of the epilepsy therapy market. It believes this market is in a "dire need of new medicines."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OVID
